Anacor Pharmaceuticals to Hold Conference Call Tomorrow, March 21, 2013 at 8am ET / 5am PT to Discuss Preliminary Results From

  Anacor Pharmaceuticals to Hold Conference Call Tomorrow, March 21, 2013 at
  8am ET / 5am PT to Discuss Preliminary Results From the Phase 2 Dose-Ranging
  Study of AN2728 in the Treatment of Adolescents With Atopic Dermatitis

Business Wire

PALO ALTO, Calif. -- March 20, 2013

Anacor Pharmaceuticals (NASDAQ:ANAC) will release preliminary results from the
Phase 2 dose-ranging study of AN2728 in the treatment of adolescents with
atopic dermatitis tomorrow, March 21, 2013 at approximately 7:00 a.m. ET. The
announcement will be followed by a conference call at 8:00 a.m. ET to discuss
the results.

The call can be accessed by dialing (877) 291-1367 (domestic) and (914)
495-8534 (international) five minutes prior to the start of the call. The call
will also be webcast live and can be accessed on the Events and Presentations
page, under Investors, on the company’s website at www.anacor.com and will be
available for three months following the call.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered eight compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — tavaborole, an antifungal for the treatment of
onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other wholly-owned clinical product
candidates — AN2718 and AN2898, which are backup compounds to tavaborole and
AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or
GSK‘052), an antibiotic for the treatment of infections caused by
Gram-negative bacteria, which previously was licensed to GlaxoSmithKlineLLC,
or GSK. GSK has returned all rights to the compound to us and we are
considering our options for further development, if any, of this compound. We
have also discovered three other compounds that we have out-licensed for
further development — two are licensed to Eli Lilly and Company for the
treatment of animal health indications and the third compound, AN5568, also
referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases
initiative, or DNDi, for human African trypanosomiasis (HAT, or sleeping
sickness). We also have a pipeline of other internally discovered topical and
systemic boron-based compounds in development. For more information, visit
http://www.anacor.com.

Contact:

Anacor Pharmaceuticals
DeDe Sheel, 650-543-7575
Investor Relations and Corporate Communications
dsheel@anacor.com